Cargando…
Prognostic factors for patients treated with abiraterone
AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evalua...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/ https://www.ncbi.nlm.nih.gov/pubmed/32025327 http://dx.doi.org/10.2144/fsoa-2019-0079 |
_version_ | 1783493780266024960 |
---|---|
author | Alvim, Cecília M Mansinho, André Paiva, Rita S Brás, Raquel Semedo, Patrícia M Lobo-Martins, Soraia da Ponte, Carolina B Macedo, Daniela Ribeiro, Leonor dos Reis, José P Fernandes, Isabel Costa, Luís |
author_facet | Alvim, Cecília M Mansinho, André Paiva, Rita S Brás, Raquel Semedo, Patrícia M Lobo-Martins, Soraia da Ponte, Carolina B Macedo, Daniela Ribeiro, Leonor dos Reis, José P Fernandes, Isabel Costa, Luís |
author_sort | Alvim, Cecília M |
collection | PubMed |
description | AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evaluation of patients with mCRPC treated with AA. RESULTS: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). CONCLUSION: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA. |
format | Online Article Text |
id | pubmed-6997918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-69979182020-02-05 Prognostic factors for patients treated with abiraterone Alvim, Cecília M Mansinho, André Paiva, Rita S Brás, Raquel Semedo, Patrícia M Lobo-Martins, Soraia da Ponte, Carolina B Macedo, Daniela Ribeiro, Leonor dos Reis, José P Fernandes, Isabel Costa, Luís Future Sci OA Research Article AIM: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). METHODS: Retrospective evaluation of patients with mCRPC treated with AA. RESULTS: 124 patients were identified. Median overall survival and progression-free survival for patients achieving PSAr versus patients without PSAr were 29.3 versus 9.7 months and 17.0 versus 5.2 months, respectively. Multivariate analysis confirmed that PSAr correlated with better overall survival (hazard ratio: 0.19; 95% CI: 0.10−0.38; p < 0.001) and progression-free survival (hazard ratio: 0.24; 95% CI: 0.14−0.41; p < 0.001). CONCLUSION: PSAr can be utilized as prognostic and predictive factors in mCRPC patients treated with AA. Future Science Ltd 2019-12-12 /pmc/articles/PMC6997918/ /pubmed/32025327 http://dx.doi.org/10.2144/fsoa-2019-0079 Text en © 2019 Cecilia Melo Alvim This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Research Article Alvim, Cecília M Mansinho, André Paiva, Rita S Brás, Raquel Semedo, Patrícia M Lobo-Martins, Soraia da Ponte, Carolina B Macedo, Daniela Ribeiro, Leonor dos Reis, José P Fernandes, Isabel Costa, Luís Prognostic factors for patients treated with abiraterone |
title | Prognostic factors for patients treated with abiraterone |
title_full | Prognostic factors for patients treated with abiraterone |
title_fullStr | Prognostic factors for patients treated with abiraterone |
title_full_unstemmed | Prognostic factors for patients treated with abiraterone |
title_short | Prognostic factors for patients treated with abiraterone |
title_sort | prognostic factors for patients treated with abiraterone |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997918/ https://www.ncbi.nlm.nih.gov/pubmed/32025327 http://dx.doi.org/10.2144/fsoa-2019-0079 |
work_keys_str_mv | AT alvimceciliam prognosticfactorsforpatientstreatedwithabiraterone AT mansinhoandre prognosticfactorsforpatientstreatedwithabiraterone AT paivaritas prognosticfactorsforpatientstreatedwithabiraterone AT brasraquel prognosticfactorsforpatientstreatedwithabiraterone AT semedopatriciam prognosticfactorsforpatientstreatedwithabiraterone AT lobomartinssoraia prognosticfactorsforpatientstreatedwithabiraterone AT dapontecarolinab prognosticfactorsforpatientstreatedwithabiraterone AT macedodaniela prognosticfactorsforpatientstreatedwithabiraterone AT ribeiroleonor prognosticfactorsforpatientstreatedwithabiraterone AT dosreisjosep prognosticfactorsforpatientstreatedwithabiraterone AT fernandesisabel prognosticfactorsforpatientstreatedwithabiraterone AT costaluis prognosticfactorsforpatientstreatedwithabiraterone |